Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Patricia Mercer

Allergy & Immunology Bowling Green, KY Medical Doctor

NPI 1619973138 CMS profile 300063

2724 Nashville Rd, Bowling Green, KY 42101

Open in the dashboard

General payments

$3,387

187 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Patricia Mercer of Bowling Green, KY is reported in the CMS Open Payments database as having received $3,387 across 187 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 50th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $318 19
2021 General $1,015 56
2020 General $638 39
2019 General $1,415 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patricia Mercer
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Patricia Mercer were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Patricia Mercer Allergy & Immunology median Middle half National median
2019 $1,415 $594 $163–$1,512 $163
2020 $638 $426 $106–$1,233 $114
2021 $1,015 $638 $157–$1,708 $132
2022 $318 $790 $205–$1,961 $149
2023 $0 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. GlaxoSmithKline, LLC. $652 43 payments
  2. AstraZeneca Pharmaceuticals LP $625 33 payments
  3. CSL Behring $317 19 payments
  4. Genentech USA, Inc. $257 10 payments
  5. Octapharma USA, Inc. $198 5 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $113 7 payments
  7. Horizon Therapeutics plc $103 6 payments
  8. Pharming Healthcare, Inc. $101 6 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $98 6 payments
  10. Shire North American Group Inc $98 5 payments
  11. Other $824 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,387 187 payments
Products named General payments · program years 2019–2022
  1. NUCALA $293 17 payments
  2. CUTAQUIG $219 6 payments
  3. Haegarda $197 11 payments
  4. FASENRA Respiratory $196 11 payments
  5. TRELEGY ELLIPTA $162 12 payments
  6. DUPIXENT $130 8 payments
  7. SPIRIVA RESPIMAT $130 8 payments
  8. FASENRA Respiratory $129 8 payments
  9. Hizentra $120 8 payments
  10. Xolair $111 9 payments
  11. Other $1,482 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record